3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Oligodendroglioma
1
Gliosarcoma
1
Glioblastoma
1
Ependymoma
1
Astrocytoma
1
Interventions
Temozolomide
12
Bevacizumab
8
Carboplatin
6
Radiotherapy
5
Erlotinib Hydrochloride
5
temsirolimus
3
Surgical Procedures, Operative
3
Irinotecan
3
IL13-PE38
3
veliparib
2
pembrolizumab
2
etoposide phosphate
2
Vorinostat
2
Specimen Handling
2
Sirolimus
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy, Conformal
2
Radiation
2
Magnetic Resonance Spectroscopy
2
Imatinib Mesylate
2
Genetic Therapy
2
Everolimus
2
Cetuximab
2
Carmustine
2
Cancer Vaccines
2
trastuzumab deruxtecan
1
transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38)
1
terameprocol
1
sonidegib
1
sodium thiosulfate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Astrocytoma
×
picropodophyllin
×
Clear all
NCT01721577
2023-05-22
AXL1717
Rush University Medical Center
Phase 1/2
Terminated
10 enrolled
8 charts